BMY Q4 2025 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.5B+1.3% YoY

Gross Profit

$8.4B67.2% margin

Operating Income

$1.4B11.4% margin

Net Income

$1.1B8.7% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

$2.0B

Free Cash Flow

$1.6B

Stock-Based Comp.

$133M

Balance Sheet

Total Assets

$90.0B

Total Liabilities

$71.5B

Stockholders' Equity

$18.5B

Cash & Equivalents

$10.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.5B	$12.3B	+1.3%
Gross Profit	$8.4B	$7.4B	+13.2%
Operating Income	$1.4B	$2.5B	-43.9%
Net Income	$1.1B	$72M	+1408.3%

Revenue Segments

Eliquis

$3.5B28%

Opdivo

$2.7B22%

Orencia

$1.0B8%

Yervoy

$809M6%

Pomalyst/Imnovid

$692M6%

Reblozyl

$666M5%

Revlimid

$602M5%

Other Growth Brands

$537M4%

Breyanzi

$392M3%

Camzyos

$353M3%

Opdualag

$350M3%

Other Legacy Brands

$199M2%

Zeposia

$159M1%

Opdivo Ovantig

$132M1%

Abecma

$100M1%

Sotyktu

$86M1%

Abraxane

$84M1%

Sprycel

$79M1%

Krazati

$56M0%

Cobenfy

$50M0%

Geographic Segments

UNITED STATES

$8.6B97%

Other Region

$309M3%